At a time when the discovery of yet another cytotoxin or combination therapy for combating cancer seems less than exciting, an old and almost forgotten theory re-emerges to bring new understanding to an age-old disease and new hopes for a cure.
The theory of cancer stem cells or "germ" cells was first proposed about 150 years ago. However, the theory, which posits that random DNA mutations can turn any cell in the body into a cancer cell, that any cell is as likely as the next to begin tumor growth, has been the basis of cancer research and therapy for many years. With this theory, the mechanism of metastasis remains a mystery, and cancer therapies are focused on ablation of rapidly dividing cells that make up the tumor with radiation, systemic cytotoxins, or both.
Stem Cell Research Renews Interest
It wasn't until researchers began working on normal human stem cells and developing tools to identify them in vivo that the cancer stem cell theory could be revisited meaningfully. In 1994, John Dick and colleagues at the University of Toronto were able to identify cancer stem cells in leukemic blood; in 2003, Michael Clarke, now at Stanford, identified cancer stem cells in breast tumors. And now the race is on. Stem cells have been found in brain, gut, skin, bone marrow, pancreas and prostate cancers. In essence, cancer stem cells are being found in every tumor that can be carefully screened for them.
The obvious difference between human stem cells and their differentiated progeny are cell surface markers such as CD44 and CD133, which can be targeted and labeled. But within tumors, there is roughly one stem cell for every 10,000 differentiated cells, making cancer stem cell identification, especially in solid tumors, very challenging.
Adult stem cells are preserved in vascular niches where they are protected and nourished and their growth is highly regulated in the normal state. Unlike other cells, they have the ability to expand in number (symmetric self-renewal in which each cell forms two "daughter" stem cells) or to self-renew (asymmetric self-renewal in which each forms one stem cell and one progenitor cell). Progenitor cells generally cannot self-renew, but go on to produce the more differentiated cells that form the tissues of the body.
Cancer Stem Cell Creation
With confirmation that cancer stem or stem-like progenitor cells are present in tumors, and with what we know about stem cells and their niche environments, the question remains: how are cancer stem cells created?
Some believe that stem-like progenitor cells suffer DNA damage, become oncogenic, and then revert to stem cells, entering the protected niche and eventually drive out normal stem cells. Others believe that stem cells become cancerous through disregulation of the signaling pathways that control their growth. This could occur in the proteins on the stem cell's surface-perhaps an accumulation of DNA mutations over time-or it could occur in other proteins involved in the intracellular signaling that regulates the stem cell growth cycle.
Hedgehog, Wnt, Notch, P63, Notch-i and Oct-4 signaling pathways, among others, have been implicated in cancer stem cell activation. Hedgehog and Wnt pathways are perhaps the most studied to date. Philip Beachy, who studies normal and pathologic functions of the Hedgehog family of proteins at Stanford University and the Howard Hughes Medical Institute, has shown that inhibition of Hedgehog signaling with the teratogen cyclopamine "...can block cell proliferative effects associated with pathway activation and can cause complete regression of aggressive human and rodent cancers growing in mice." In addition, he says, "Hedgehog and Wnt are really sister pathways that may be fairly fundamental in many types of cancer."
Although some researchers remain skeptical about cancer stem cell theory, the basic mechanism of metastasis now seems obvious, the observation that tumors ablated by radiation or chemotherapy sometimes re-grow rapidly now makes sense, and the mechanism by which vascular endothelial growth factor (VEGF) antagonists stop tumor growth is also clear because they inhibit the vascularization of cancer stem cell niches and tumors.
Where The Opportunities Are
Here are some of the new therapeutic opportunities being developed based on the theory of cancer stem cells:
• Monoclonal antibodies to cancer stem cells are combined with cytotoxic payloads to seek and destroy the few cancer stem cells rather than whole tumors and normal cells as well.
• The immune system is used to combat cancer stem cells specifically via a cancer vaccine.
• Nontoxic compounds can be identified to modulate the signaling pathways, such as Hedgehog and Wnt, that appear to be out of control in tumor progression.
• There will likely be a more enlightened role for VEGF antagonists to play in the control of cancer stem cell "niches", as well.
In a February 2006 New York Times article, Robert Weinburg, member of the Whitehead Institute for Biomedical Research and Professor of Biology at MIT, was quoted as saying that pharmaceutical companies are "waiting for more academic research before they take a clear view on how to proceed. Our knowledge base is still rather fragmentary, and we need another year or two of research before we can say to pharmaceutical companies you should do this or that." That time may be soon.
Results Starting To Be Seen
In May 2001, Novartis received FDA approval for Imatinib Mesylate (Gleevec™) for treatment of chronic myelogenous leukemia and later for gastrointestinal stromal tumors. Imatinib Mesylate is the first tyrosine kinase inhibitor approved for cancer treatment.
Genentech has established a venture fund with OncoMed, whose co-founders, Michael Clarke and Max Wicha are leaders in the field of cancer stem cell research. Genentech's collaborative development projects with Curis, a drug development company focused on control of signaling pathways primarily for cancer therapy, include a Hedgehog pathway antagonist project established in 2003 and a 2005 licensing agreement for small molecule modulators of a cell proliferation signaling pathway.
Immunocellular Therapeutics, Ltd., a Los Angeles-based company with vaccine technology licensed exclusively from Cedars-Sinai Medical Center, is beginning Phase I trials on a dendritic cell-based vaccine designed to use the immune system to ward off brain tumors.
On March 7, 2007, Stemline Therapeutics announced the in-licensing of an interleukin-3 receptor antagonist, SL-401, from the Scott & White Cancer Research Institute/Texas A&M Health Science Center College of Medicine. SL-401 had shown promising results in a multi-center Phase I trial in patients with acute myeloid leukemia.
And, Geron Corporation, focusing on cell cycle regulation in embryonic and cancer stem cells by telomeres, has several telomerase inhibitor programs. Its lead compound, GRN163L, an oligonucleotide with telomerase inhibiting activity, is in Phase I/II clinical trials for chronic lymphocytic leukemia.
Nerac Inc. is a global research and advisory firm for companies developing innovative products and technologies. Nerac Analysts deliver custom assessments of product and technology development opportunities, competitor intelligence, intellectual property strategies, and compliance requirements through a proven blended approach to custom analysis: review of technical knowledge, investigation of intellectual property, and appraisal of business impacts. Nerac deploys analysts in diverse disciplines to help clients discover new applications, serving as a catalyst for new thinking and creative approaches to business problems or identifying strategic growth opportunities. On the web at http://www.nerac.com
Colorado Mesothelioma Lawyers